GALYM IMANBAYEV
Directeur/Membre du Conseil chez Kirilys Therapeutics, Inc.
Profil
GALYM IMANBAYEV is currently working as a Director at Kirilys Therapeutics, Inc. and as a Partner at Lightspeed Management Co LLC.
He completed his undergraduate degree from Stanford University.
Postes actifs de GALYM IMANBAYEV
| Sociétés | Poste | Début |
|---|---|---|
Lightspeed Management Co LLC
 Lightspeed Management Co LLC Investment ManagersFinance Lightspeed Management Co. LLC (Lightspeed Venture Partners) is a venture capital firm founded in 1971. The firm is headquartered in Menlo Park, California. It was formerly known as Weiss, Peck & Greer Venture Partners. | Private Equity Investor | 01/01/2020 |
Kirilys Therapeutics, Inc.
 Kirilys Therapeutics, Inc. Medical/Nursing ServicesHealth Services Kirilys Therapeutics, Inc. is an American preclinical-stage biopharmaceutical company that focuses on developing multiple precision oncology assets. The company is based in California and is committed to advancing the field of oncology. The company's initial asset is KRLS-017, a novel CDK7 inhibitor that has the potential to improve the treatment of multiple cancers. Kirilys Therapeutics was founded by Takeshi Takahashi, Brian Taylor Slingsby, and Kapil Dhingra, with Brian Taylor Slingsby serving as the CEO since incorporation. | Directeur/Membre du Conseil | - |
Formation de GALYM IMANBAYEV
| Stanford University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Lightspeed Management Co LLC
Lightspeed Management Co LLC Investment ManagersFinance Lightspeed Management Co. LLC (Lightspeed Venture Partners) is a venture capital firm founded in 1971. The firm is headquartered in Menlo Park, California. It was formerly known as Weiss, Peck & Greer Venture Partners. | Finance |
Kirilys Therapeutics, Inc.
Kirilys Therapeutics, Inc. Medical/Nursing ServicesHealth Services Kirilys Therapeutics, Inc. is an American preclinical-stage biopharmaceutical company that focuses on developing multiple precision oncology assets. The company is based in California and is committed to advancing the field of oncology. The company's initial asset is KRLS-017, a novel CDK7 inhibitor that has the potential to improve the treatment of multiple cancers. Kirilys Therapeutics was founded by Takeshi Takahashi, Brian Taylor Slingsby, and Kapil Dhingra, with Brian Taylor Slingsby serving as the CEO since incorporation. | Health Services |
